Expertise in
8
conditions

Dr. Kenneth P. Byrd

Hematology Oncology | Hematology
University Of Kansas Hospital Authority
2650 Shawnee Mission Pkwy, 
Westwood, KS 
Accepting New Patients
Offers Telehealth
Expertise in
8
conditions
University Of Kansas Hospital Authority
2650 Shawnee Mission Pkwy, 
Westwood, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kenneth Byrd is a Hematologist Oncology specialist and a Hematologist in Westwood, Kansas. Dr. Byrd is highly rated in 8 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Splenectomy. Dr. Byrd is currently accepting new patients.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Licenses
Internal Medicine in KS
Hospital Affiliations
University Of Kansas Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

UNIVERSITY OF KANSAS HOSPITAL AUTHORITY
2650 Shawnee Mission Pkwy, Westwood, KS 66205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Suspended
Publish Date: September 22, 2025
Intervention Type: Biological
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Azacitidine, Pembrolizumab, Venetoclax
Study Phase: Phase 2
View 3 Less Clinical Trials

7 Total Publications

Multi-institutional analysis of outcomes in acute myeloid leukemia patients with central nervous system involvement.
Multi-institutional analysis of outcomes in acute myeloid leukemia patients with central nervous system involvement.
Journal: Leukemia & lymphoma
Published: August 17, 2023
Similar Doctors
Expertise in
32
conditions
Dr. Leyla O. Shune
Hematology Oncology | Hematology | Oncology
Expertise in
32
conditions
Dr. Leyla O. Shune
Hematology Oncology | Hematology | Oncology

University Of Kansas Hospital Authority

2650 Shawnee Mission Pkwy, 
Westwood, KS 
 (0.1 miles away)
913-588-7750
Languages Spoken:
English, Somali, Swahili, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Leyla Shune is a Hematologist Oncology specialist and a Hematologist in Westwood, Kansas. Dr. Shune is highly rated in 32 conditions, according to our data. Her top areas of expertise are Relapsed Refractory Multiple Myeloma (RRMM), Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Shune is currently accepting new patients.

Expertise in
15
conditions
Dr. Tara L. Lin
Hematology Oncology | Hematology | Oncology
Expertise in
15
conditions
Dr. Tara L. Lin
Hematology Oncology | Hematology | Oncology

University Of Kansas Hospital Authority

3901 Rainbow Blvd, 
Kansas City, KS 
 (1.8 miles away)
913-588-7743
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tara Lin is a Hematologist Oncology specialist and a Hematologist in Kansas City, Kansas. Dr. Lin is highly rated in 15 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Lin is currently accepting new patients.

Expertise in
40
conditions
Dr. Sunil H. Abhyankar
Hematology Oncology | Hematology | Oncology
Expertise in
40
conditions
Dr. Sunil H. Abhyankar
Hematology Oncology | Hematology | Oncology

University Of Kansas Hospital Authority

3901 Rainbow Blvd, 
Kansas City, KS 
 (1.8 miles away)
913-588-7743
Languages Spoken:
English, Hindi, Marathi
See accepted insurances
Accepting New Patients
Offers Telehealth

Sunil Abhyankar is a Hematologist Oncology specialist and a Hematologist in Kansas City, Kansas. Dr. Abhyankar is highly rated in 40 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Abhyankar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Byrd's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile